Question special
Lead Moderator

In the past week the FDA recommended the approval of evolocumab and alirocumab injections. Our authors and experts have talked about the exciting benefits of PCSK9 inhibitors, as well as their barriers of cost. Do ezetimibe and PCSK9 inhibitors target different types of patient populations that would benefit more from one drug over the other? Could these monoclonal antibodies eventually be combined with ezetimibe to synergistically reduce LDL cholesterol levels? What are your thoughts about the direction of non-statin therapy research?